Banco Santander and the Spanish Chamber of Commerce present the 2025 National SME of the Year Award
- A total of 1,770 companies participated in the ninth edition of the National SME of the Year Award.
- The award was presented by King Felipe VI to Laureano Simón, founder of Oncomatryx, at a ceremony held today at the Banco Santander headquarters in Madrid.
- This recognition confirms Oncomatryx’s innovation in the field of oncology and represents a hopeful milestone in the fight against cancer.
Thursday, February 19, 2026. Oncomatryx has received the Innovation and Digitalization Award at the 9th edition of the National SME of the Year Awards, organized by Banco Santander and the Spanish Chamber of Commerce. King Felipe VI presented the award to Laureano Simón, founder of the company, at a ceremony held today at the Banco Santander headquarters in Madrid.
A total of 1,770 companies from across the country participated in this ninth edition, consolidating these awards as one of the most important business recognitions for the SME sector in Spain.
This award recognizes Oncomatryx’s commitment to research and development of innovative treatments for solid cancers. This work drives scientific progress and represents hope for people suffering from this disease.
This reinforces Oncomatryx’s position as a leading biotechnology company in the field of oncology, endorsing its commitment to innovation, scientific excellence, and improving patients’ quality of life.
About Oncomatryx
Oncomatryx, based in the Bizkaia Technology Park, has discovered new mechanisms and proteins in the tumor microenvironment—the cells and extracellular matrix surrounding the tumor—that promote its aggressiveness, its ability to evade the immune system, its resistance to treatment, and its ability to spread to other organs. This knowledge has enabled Oncomatryx to develop pioneering therapies that act precisely on these key factors with a precision drug known as antibody-drug conjugates (ADCs).
Thanks to its own research, chemistry, and conjugation laboratories, Oncomatryx has established itself as the most advanced company in Europe in this field, covering everything from the initial discovery phase to clinical development. In addition, together with its subsidiaries Quimatryx and Nelum, the company has research centers in the Zamudio and Miramón technology parks (Basque Country) and in Research Triangle Park in North Carolina (USA), thus strengthening its international presence and leadership in biomedical innovation.